157 related articles for article (PubMed ID: 28184030)
21. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes.
Langeberg WJ; Tahir SA; Feng Z; Kwon EM; Ostrander EA; Thompson TC; Stanford JL
Prostate; 2010 Jun; 70(9):1020-35. PubMed ID: 20209490
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility loci associated with prostate cancer progression and mortality.
Gallagher DJ; Vijai J; Cronin AM; Bhatia J; Vickers AJ; Gaudet MM; Fine S; Reuter V; Scher HI; Halldén C; Dutra-Clarke A; Klein RJ; Scardino PT; Eastham JA; Lilja H; Kirchhoff T; Offit K
Clin Cancer Res; 2010 May; 16(10):2819-32. PubMed ID: 20460480
[TBL] [Abstract][Full Text] [Related]
23. Genetic Variants in Caveolin-1 and RhoA/ROCK1 Are Associated with Clear Cell Renal Cell Carcinoma Risk in a Chinese Population.
Zhao R; Liu K; Huang Z; Wang J; Pan Y; Huang Y; Deng X; Liu J; Qin C; Cheng G; Hua L; Li J; Yin C
PLoS One; 2015; 10(6):e0128771. PubMed ID: 26066055
[TBL] [Abstract][Full Text] [Related]
24. Genetic interaction analysis of TCF7L2 for biochemical recurrence after radical prostatectomy in localized prostate cancer.
Chen CS; Huang CY; Huang SP; Lin VC; Yu CC; Chang TY; Bao BY
Int J Med Sci; 2015; 12(3):243-7. PubMed ID: 25678841
[TBL] [Abstract][Full Text] [Related]
25. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
[TBL] [Abstract][Full Text] [Related]
26. Single nucleotide polymorphisms in DKK3 gene are associated with prostate cancer risk and progression.
Kim MS; Lee HN; Kim HJ; Myung SC
Int Braz J Urol; 2015; 41(5):869-97. PubMed ID: 26689513
[TBL] [Abstract][Full Text] [Related]
27. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer.
Chen YC; Giovannucci E; Lazarus R; Kraft P; Ketkar S; Hunter DJ
Cancer Res; 2005 Dec; 65(24):11771-8. PubMed ID: 16357190
[TBL] [Abstract][Full Text] [Related]
28. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
29. Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence.
Gerstenberger JP; Bauer SR; Van Blarigan EL; Sosa E; Song X; Witte JS; Carroll PR; Chan JM
Prostate; 2015 Jan; 75(1):60-9. PubMed ID: 25284284
[TBL] [Abstract][Full Text] [Related]
30. Investigation of Interleukin-1β Polymorphisms in Prostate Cancer.
Yencilek F; Yildirim A; Yilmaz SG; Altinkilic EM; Dalan AB; Bastug Y; Isbir T
Anticancer Res; 2015 Nov; 35(11):6057-61. PubMed ID: 26504029
[TBL] [Abstract][Full Text] [Related]
31. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy.
Meyer A; Coinac I; Bogdanova N; Dubrowinskaja N; Turmanov N; Haubold S; Schürmann P; Imkamp F; von Klot C; Merseburger AS; Machtens S; Bremer M; Hillemanns P; Kuczyk MA; Karstens JH; Serth J; Dörk T
Urol Oncol; 2013 Jan; 31(1):74-81. PubMed ID: 21396839
[TBL] [Abstract][Full Text] [Related]
33. Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.
Lin VC; Huang CY; Lee YC; Yu CC; Chang TY; Lu TL; Huang SP; Bao BY
Arch Toxicol; 2014 Apr; 88(4):901-11. PubMed ID: 24448834
[TBL] [Abstract][Full Text] [Related]
34. A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer.
Absenger G; Szkandera J; Stotz M; Pichler M; Winder T; Langsenlehner T; Langsenlehner U; Samonigg H; Renner W; Gerger A
Mol Carcinog; 2013 Nov; 52 Suppl 1():E96-102. PubMed ID: 23625573
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
36. Functional polymorphisms of ATP citrate lyase gene predicts clinical outcome of patients with advanced colorectal cancer.
Xie S; Zhou F; Wang J; Cao H; Chen Y; Liu X; Zhang Z; Dai J; He X
World J Surg Oncol; 2015 Feb; 13():42. PubMed ID: 25890184
[TBL] [Abstract][Full Text] [Related]
37. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
[TBL] [Abstract][Full Text] [Related]
38. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
39. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
[TBL] [Abstract][Full Text] [Related]
40. The rs6983267 SNP is associated with MYC transcription efficiency, which promotes progression and worsens prognosis of colorectal cancer.
Takatsuno Y; Mimori K; Yamamoto K; Sato T; Niida A; Inoue H; Imoto S; Kawano S; Yamaguchi R; Toh H; Iinuma H; Ishimaru S; Ishii H; Suzuki S; Tokudome S; Watanabe M; Tanaka J; Kudo SE; Mochizuki H; Kusunoki M; Yamada K; Shimada Y; Moriya Y; Miyano S; Sugihara K; Mori M
Ann Surg Oncol; 2013 Apr; 20(4):1395-402. PubMed ID: 22976378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
